Please replace Claims 1, 2, and 4 with the following clean versions:

1. (Amended 4 times) A method of modulating the activity of metabotropic glutamate receptors, said method comprising:

contacting said receptors with at least one compound having the structure **A-L-B** or enantiomers, diastereomeric isomers or mixtures of any two or more thereof, or pharmaceutically acceptable salts thereof, in an amount sufficient to modulate the activity of said metabotropic glutamate receptors wherein:

A is thiazolyl optionally substituted with 1 or 2 independent halogen, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted aryl, heterocycle, mercapto, nitro, carboxyl, carbamate, carboxamide, hydroxy, ester, cyano, amine, amide, amidine, amido, sulfonyl or sulfonamide;

L is alkynylene; and

B is substituted or unsubstituted aryl.

2. (Amended 3 times) The method according to claim 1, wherein said metabotropic glutamate receptor is a Group 1 metabotropic glutamate receptor.

4. (Amended 4 times) A method for treating a disease condition which is treatable by modulation of the activity of metabotropic glutamate receptors, said method comprising:

administering to a patient having said disease condition, a therapeutically effective amount which is sufficient to modulate the activity of metabotropic glutamate receptors, of at least one compound having the structure **A-L-B** or enantiomers, diastereomeric isomers or mixtures of any two or more thereof, or pharmaceutically acceptable salts thereof, wherein:

A is thiazolyl optionally substituted with 1 or 2 independent halogen, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted aryl, heterocycle, mercapto, nitro, carboxyl, carbamate, carboxamide, hydroxy, ester, cyano, amine, amide, amidine, amido, sulfonyl or sulfonamide;

L is alkynylene; and

B is substituted or unsubstituted aryl.